AU Patent

AU2021255723A1 — Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof

Assigned to ESSA Pharma Inc · Expires 2022-12-08 · 3y expired

What this patent protects

The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/o…

USPTO Abstract

The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021255723A1
Jurisdiction
AU
Classification
—
Expires
2022-12-08
Drug substance claim
No
Drug product claim
No
Assignee
ESSA Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.